# An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

> **NCT02103439** · PHASE3 · COMPLETED · sponsor: **Biocad** · enrollment: 140 (actual)

## Conditions studied

- Hepatitis
- Hepatitis C
- Hepatitis C/ Human Immunodeficiency Virus Coinfection

## Interventions

- **DRUG:** Algeron
- **DRUG:** PegIntron

## Key facts

- **NCT ID:** NCT02103439
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-06
- **Primary completion:** 2015-08-26
- **Final completion:** 2015-08-26
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02103439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02103439, "An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT02103439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*